Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 308

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 308
---
 income in amount of $321and $31, respectively.

NOTE 8:- WARRANTS
LIABILITY

In
March 2022, in conjunction with the Merger with HCCC, the Company issued 13,749,984 2,142,000 five years 11.50 144,123 144,123 No

As
of December 31, 2024, a total of 13,605,561 2,142,000

Public Warrants

Each whole warrant will entitle the
registered holder to purchase one Ordinary share. No fractional warrants will be issued and only whole warrants will trade.
No warrant will be exercisable and the Company will not be obligated to issue an Ordinary share upon exercise of a warrant unless the
Ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of
the state of residence of the registered holder of the warrants. In no event is the Company required to net cash settle any warrant. During
any period if the Company has failed to maintain an effective registration statement, warrant holders will be able to, until such time
there is an effective registration statement, exercise their warrants on a “cashless basis.”

F-20

ALPHA TAU
MEDICAL LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U. S. dollars
in thousands (except share and per share data)

NOTE 8:- WARRANTS
LIABILITY (Cont.)

Once the warrants become exercisable,
the Company may call the warrants for redemption:

  In                      

  At a price of $ 0.01 per warrant;  

  Upon not less than 30 days’ prior written notice of redemption (the “ 30 -day redemption period”) to each warrant holder; and  

  If, and only if, the closing price of the Ordinary shares equals or exceeds $ 18.00 per share (subject to standard adjustments) for any 20 trading days within a 30-trading day period ending thr...  

If the Company calls the warrants for
redemption for cash the Company’s management will have the option to require any holder that wishes to exercise his, her or its
warrant to do so on a “cashless basis.” If the Company’s management takes advantage of this option, all holders of warrants
would pay the exercise price by surrendering their warrants for that number of shares of Ordinary shares equal to the quotient obtained
by